Loading
Life sciences · Journal article
Advanced Science · September 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Therapeutic strategies for glioblastoma have progressed considerably over recent decades. Despite the development of new biomedical technologies and advances in our understanding of physiology and disease progression, effective drug delivery to brain cancer remains a significant challenge. The challenge is delivering therapeutics to the correct location without losing therapeutics to non‐desirable cells as well as overcoming the low permeability posed by the blood‐brain barrier. This could be tackled by conjugating a specific targeting agent to the therapeutic or drug delivery system to guide, such as an aptamer. Aptamers are short, single‐stranded oligonucleotides with high selectivity and specificity for their targets, making them primed for a vast array of diagnostic and therapeutic applications. Aptamers are powerful molecular tools with the potential to overcome many of the challenges inherent in treating brain‐based diseases. Here is discussed the use of aptamers, specifically as drug delivery vehicles, for the treatment of glioblastoma. There are a multitude of drug delivery aptamers in development, each with their own optimized formulation and drug delivery strategy. This review systematically and comprehensively details every drug delivery system that includes aptamers as a glioblastoma therapy that has been published to date.